Overview of OxLDL and its impact on cardiovascular health: Focus on atherosclerosis
Novo Nordisk is planning a higher-dose version (CagriSema 2.4/7.2 mg, pairing standard cagrilintide with Wegovy HD-level semaglutide) in a new Phase 3 trial starting H2 2026
Researchers continue to investigate these observations as part of broader studies into cellular recovery following neurological injury
Jinquan T, Vorum H, Grnhj Larsen C, Madsen P, Rasmussen HH, Gesser B, Etzerodt M, Honor B, Celis JE, Thestrup-Pedersen K: Psoriasin: a novel chemotactic protein
GLP-1 Receptor Agonist Reconstitution Bacteriostatic Water is compatible with GLP-1 receptor agonist peptides including Semaglutide and native GLP-1 for laboratory research use